Literature DB >> 24523836

New agents to treat lower urinary tract and pelvic floor disorders.

Cornelius Kelleher1.   

Abstract

For patients with overactive bladder and a suboptimal response to antimuscarinic therapy, there are several options to consider including alteration of the antimuscarinic regimen, switching to an agent with an alternate mechanism of action (i.e., mirabegron), posterior tibial nerve stimulation, or botulinum toxin. These options are summarized in this brief review.

Entities:  

Year:  2013        PMID: 24523836      PMCID: PMC3919187          DOI: 10.5489/cuaj.1615

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  12 in total

1.  Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial.

Authors:  Kenneth M Peters; Donna J Carrico; Ramon A Perez-Marrero; Ansar U Khan; Leslie S Wooldridge; Gregory L Davis; Scott A Macdiarmid
Journal:  J Urol       Date:  2010-02-20       Impact factor: 7.450

2.  Comparing adherence and persistence across 6 chronic medication classes.

Authors:  Jason Yeaw; Joshua S Benner; John G Walt; Sergey Sian; Daniel B Smith
Journal:  J Manag Care Pharm       Date:  2009 Nov-Dec

Review 3.  Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome.

Authors:  Christopher R Chapple; Matt T Rosenberg; Francisco J Brenes
Journal:  BJU Int       Date:  2009-04-17       Impact factor: 5.588

Review 4.  The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.

Authors:  Christopher R Chapple; Vik Khullar; Zahava Gabriel; Dominic Muston; Caty Ebel Bitoun; David Weinstein
Journal:  Eur Urol       Date:  2008-06-20       Impact factor: 20.096

5.  Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.

Authors:  Michael B Chancellor; Norman Zinner; Kristene Whitmore; Kathleen Kobashi; Jeffrey A Snyder; Paul Siami; Mickey Karram; Christine Laramée; James P Capo'; Raafat Seifeldin; Sergio Forero-Schwanhaeuser; Indrani Nandy
Journal:  Clin Ther       Date:  2008-10       Impact factor: 3.393

Review 6.  A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder.

Authors:  Giacomo Novara; Antonio Galfano; Silvia Secco; Carolina D'Elia; Stefano Cavalleri; Vincenzo Ficarra; Walter Artibani
Journal:  Eur Urol       Date:  2008-07-09       Impact factor: 20.096

7.  Patient-reported reasons for discontinuing overactive bladder medication.

Authors:  Joshua S Benner; Michael B Nichol; Eric S Rovner; Zhanna Jumadilova; Jose Alvir; Mohamed Hussein; Kristina Fanning; Jeffrey N Trocio; Linda Brubaker
Journal:  BJU Int       Date:  2009-11-12       Impact factor: 5.588

8.  Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.

Authors:  Arun Sahai; Mohammad Shamim Khan; Prokar Dasgupta
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

9.  Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.

Authors:  Vik Khullar; Gerard Amarenco; Javier C Angulo; Javier Cambronero; Kjetil Høye; Ian Milsom; Piotr Radziszewski; Tomasz Rechberger; Peter Boerrigter; Ted Drogendijk; Marianne Wooning; Christopher Chapple
Journal:  Eur Urol       Date:  2012-11-06       Impact factor: 20.096

10.  Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.

Authors:  Christopher R Chapple; Steven A Kaplan; David Mitcheson; Jiri Klecka; Jana Cummings; Ted Drogendijk; Caroline Dorrepaal; Nancy Martin
Journal:  Eur Urol       Date:  2012-11-06       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.